Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Director Jeffery A. Smisek Sells 6,642 Shares of Stock

Finch Therapeutics Group, Inc. (NASDAQ:FNCHGet Free Report) Director Jeffery A. Smisek sold 6,642 shares of the company’s stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $2.57, for a total transaction of $17,069.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Finch Therapeutics Group Stock Performance

NASDAQ FNCH opened at $2.60 on Friday. The company has a 50-day simple moving average of $2.65 and a two-hundred day simple moving average of $3.58. Finch Therapeutics Group, Inc. has a 12-month low of $2.19 and a 12-month high of $16.74.

Finch Therapeutics Group (NASDAQ:FNCHGet Free Report) last issued its quarterly earnings data on Monday, March 25th. The company reported ($1.89) EPS for the quarter.

Hedge Funds Weigh In On Finch Therapeutics Group

A number of institutional investors have recently bought and sold shares of the stock. MSD Partners L.P. bought a new position in shares of Finch Therapeutics Group during the third quarter valued at approximately $26,000. BlackRock Inc. increased its stake in shares of Finch Therapeutics Group by 2.3% during the first quarter. BlackRock Inc. now owns 404,931 shares of the company’s stock valued at $2,038,000 after purchasing an additional 9,149 shares in the last quarter. Millennium Management LLC bought a new position in shares of Finch Therapeutics Group during the second quarter valued at approximately $259,000. Renaissance Technologies LLC increased its stake in shares of Finch Therapeutics Group by 19.4% during the first quarter. Renaissance Technologies LLC now owns 45,000 shares of the company’s stock valued at $226,000 after purchasing an additional 7,314 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Finch Therapeutics Group by 10.0% during the third quarter. Vanguard Group Inc. now owns 35,939 shares of the company’s stock valued at $186,000 after purchasing an additional 3,263 shares in the last quarter. 21.77% of the stock is owned by institutional investors.

About Finch Therapeutics Group

(Get Free Report)

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.

Featured Stories

Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.